241 related articles for article (PubMed ID: 28762004)
21. The potential of PARP inhibitors in neuro-oncology.
Carruthers R; Chalmers AJ
CNS Oncol; 2012 Sep; 1(1):85-97. PubMed ID: 25054302
[TBL] [Abstract][Full Text] [Related]
22. Hypoxic cell radiosensitizers in the treatment of malignant brain tumors.
Gutin PH; Wara WM; Phillips TL; Wilson CB
Neurosurgery; 1980 May; 6(5):567-76. PubMed ID: 6251398
[TBL] [Abstract][Full Text] [Related]
23. Molecular Evolution of
Draaisma K; Chatzipli A; Taphoorn M; Kerkhof M; Weyerbrock A; Sanson M; Hoeben A; Lukacova S; Lombardi G; Leenstra S; Hanse M; Fleischeuer R; Watts C; McAbee J; Angelopoulos N; Gorlia T; Golfinopoulos V; Kros JM; Verhaak RGW; Bours V; van den Bent MJ; McDermott U; Robe PA; French PJ
J Clin Oncol; 2020 Jan; 38(1):81-99. PubMed ID: 31743054
[TBL] [Abstract][Full Text] [Related]
24. DTCM-glutarimide Delays Growth and Radiosensitizes Glioblastoma.
Roberto GM; Paiva HH; Botelho de Souza LE; Pezuk JA; Vieira GM; de Oliveira HF; Umezawa K; Tone LG; Brassesco MS
Anticancer Agents Med Chem; 2018; 18(9):1323-1329. PubMed ID: 29683097
[TBL] [Abstract][Full Text] [Related]
25. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
[TBL] [Abstract][Full Text] [Related]
26. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme.
Chang JE; Khuntia D; Robins HI; Mehta MP
Clin Adv Hematol Oncol; 2007 Nov; 5(11):894-902, 907-15. PubMed ID: 18185489
[TBL] [Abstract][Full Text] [Related]
27. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
28. Local DNA Repair Inhibition for Sustained Radiosensitization of High-Grade Gliomas.
King AR; Corso CD; Chen EM; Song E; Bongiorni P; Chen Z; Sundaram RK; Bindra RS; Saltzman WM
Mol Cancer Ther; 2017 Aug; 16(8):1456-1469. PubMed ID: 28566437
[TBL] [Abstract][Full Text] [Related]
29. Roles of Valproic Acid in Improving Radiation Therapy for Glioblastoma: a Review of Literature Focusing on Clinical Evidence.
Ochiai S; Nomoto Y; Yamashita Y; Watanabe Y; Toyomasu Y; Kawamura T; Takada A; Ii N; Kobayashi S; Sakuma H
Asian Pac J Cancer Prev; 2016; 17(2):463-6. PubMed ID: 26925628
[TBL] [Abstract][Full Text] [Related]
30. ShRNA-based POLD2 expression knockdown sensitizes glioblastoma to DNA-Damaging therapeutics.
Xu Q; Hu C; Zhu Y; Wang K; Lal B; Li L; Tang J; Wei S; Huang G; Xia S; Lv S; Laterra J; Jiang Y; Li Y
Cancer Lett; 2020 Jul; 482():126-135. PubMed ID: 31954770
[TBL] [Abstract][Full Text] [Related]
31. Radiosensitizing high-Z metal nanoparticles for enhanced radiotherapy of glioblastoma multiforme.
Choi J; Kim G; Cho SB; Im HJ
J Nanobiotechnology; 2020 Sep; 18(1):122. PubMed ID: 32883290
[TBL] [Abstract][Full Text] [Related]
32. Glioblastoma recurrent cells switch between ATM and ATR pathway as an alternative strategy to survive radiation stress.
Kaur E; Ketkar M; Dutt S
Med Oncol; 2022 Feb; 39(5):50. PubMed ID: 35150325
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer.
Sigmond J; Honeywell RJ; Postma TJ; Dirven CM; de Lange SM; van der Born K; Laan AC; Baayen JC; Van Groeningen CJ; Bergman AM; Giaccone G; Peters GJ
Ann Oncol; 2009 Jan; 20(1):182-7. PubMed ID: 18701427
[TBL] [Abstract][Full Text] [Related]
34. New Directions in the Treatment of Glioblastoma.
Reitman ZJ; Winkler F; Elia AEH
Semin Neurol; 2018 Feb; 38(1):50-61. PubMed ID: 29548052
[TBL] [Abstract][Full Text] [Related]
35. Glioblastoma heterogeneity at single cell resolution.
Eisenbarth D; Wang YA
Oncogene; 2023 Jun; 42(27):2155-2165. PubMed ID: 37277603
[TBL] [Abstract][Full Text] [Related]
36. Newly Synthesized DNA Methyltransferase Inhibitors as Radiosensitizers for Human Lung Cancer and Glioblastoma Cells.
Wee CW; Kim JH; Kim HJ; Kang HC; Suh SY; Shin BS; Ma E; Kim IH
Anticancer Res; 2021 Feb; 41(2):757-764. PubMed ID: 33517280
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.
Kioi M; Vogel H; Schultz G; Hoffman RM; Harsh GR; Brown JM
J Clin Invest; 2010 Mar; 120(3):694-705. PubMed ID: 20179352
[TBL] [Abstract][Full Text] [Related]
38. Preclinical Risk Evaluation of Normal Tissue Injury With Novel Radiosensitizers.
Dragojevic S; Ji J; Singh PK; Connors MA; Mutter RW; Lester SC; Talele SM; Zhang W; Carlson BL; Remmes NB; Park SS; Elmquist WF; Krishnan S; Tryggestad EJ; Sarkaria JN
Int J Radiat Oncol Biol Phys; 2021 Dec; 111(5):e54-e62. PubMed ID: 34400266
[TBL] [Abstract][Full Text] [Related]
39. Temporal stability of MGMT promoter methylation in glioblastoma patients undergoing STUPP protocol.
O'Regan CJ; Kearney H; Beausang A; Farrell MA; Brett FM; Cryan JB; Loftus TE; Buckley PG
J Neurooncol; 2018 Apr; 137(2):233-240. PubMed ID: 29264834
[TBL] [Abstract][Full Text] [Related]
40. Current Landscape and Future Prospects of Radiation Sensitizers for Malignant Brain Tumors: A Systematic Review.
Beg U; Snyder BM; Madhani SI; Hamidi N; Padmanaban V; Tuanquin LC; Kruser TJ; Connor J; Mansouri A
World Neurosurg; 2021 Jul; 151():e839-e856. PubMed ID: 33974987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
